National and Kapodistrian University of Athens
Βιοδείκτες ακτινολογικής εξέλιξης στην αγκυλοποιητική σπονδυλίτιδα
Abstract
dc:descriptionBackground: Ankylosing spondylitis (AS) is a prototype of a group of diseases called Spondyloarthritides. The prevalence for the disease is 0.2-0.9%. Men are affected more often than women (ratio 2:1). The disease symptoms are morning stiffness and inflammatory low back pain, which improves with exercise. AS predominantly affects the axial skeleton with sacroiliac joint involvement (sacroiliitis) and syndesmophyte formation as its hallmark, causing decreased spinal mobility. Its striking feature is bone remodeling with new cartilage and bone formation leading to ankylosis. In contrast to the classical structural changes in the spine, hip joint inflammation in AS does not lead to formation of new bone but results in bone erosions and subsequent joint destruction. The aim of this study is the evaluation of radiographic progression both in spine and hip and the estimation of potential biomarkers.Methods: 100 AS patients (83 men, age: 49.5±15 years, disease duration: 24±4 years) were included in this 2-year prospective study. Fifty two patients were initially anti-TNF treatment-naïve. After entering the study cohort, thirty one of them with high disease activity started anti-TNF treatment. The patients’ disease activity and functional limitation, prior entering anti-TNF treatment, were recorded by Bath AS Disease Index (BASDAI), Ankylosing Spondylitis Disease Activity Score (ASDAS-CRP/ESR), Bath AS Functional Index (BASFI) and Bath AS Metrology Index (BASMI). Spinal X-rays were scored by mSASS-score. Both hips were scored using BASRI-hip score and mean joint space width (MJSW), a quantitative scoring method, previously applied in hip osteoarthritis. TL1A (TNF-like cytokine 1A, member of TNFa superfamily, which is pathogenetically involved in inflammatory bowel disease), Periostin (a matricellular protein, expressed in periosteum) and Semaphorin-4D (a recently identified coupling factor that regulates bone formation) were evaluated as potential biomarkers of radiographic progression in AS. Serum concentrations of those proteins were measured by ELISA. Additionally, the classic inflammatory markers CRP and ESR were measured in the same serum. Age and sex-matched healthy individuals served as controls.Results: As far as radiographic development in the spine is concerned, 84 out of 100 patients were evaluated, because the remaining 16 showed total bridging at the initial plain X-Rays of cervical and lumbar spine (mSASS-score=72). Definite radiographic progression in spine (ΔmSASSS>2/2years) was evident in 27 of 84 patients (32%). In particular, radiographic progression was evident in 17 of 38 anti-TNF-treated patients(44.7 %), in 8 of 28 (29%) anti-TNF-treatment naive at baseline who started treatment with TNFa inhibitors after entering the study, but only in 2 of 18 patients (11%), who remained anti-TNF-treatment naive through 2 years follow-up period. Presence of syndesmophytes (OR: 6.4, CI: 1.4-30.4), elevated ESR levels (>20 mm/hr) at baseline (OR: 5.7, CI: 1.3- 24.3) and elevated time averaged CRP levels (>5mg/L) (OR: 9.1, CI: 1.9 - 42.4) were identified as independent prognostic factors for its development. In anti-TNF-treated group, high disease activity during treatment (CRP time averaged>5 mg/L, OR: 6.2, CI: 1.2-31) was a prognostic factor of radiographic deterioration in the spine. Regarding radiographic progression of hip arthritis, in 38 patients with hip involvement at baseline, both BASRI-h score and MJSW remained unchanged after 2 years (BASRI-h-baseline: 2.5±0.86 vs. follow-up end: 2.5±0.86, P=NS and MJSW-baseline: 3.5±0.9mm vs. follow-up end: 3.4±0.8mm, P=NS). In a retrospective substudy of 23 anti-TNF-treated patients with baseline hip involvement, the aforementioned measurements were not reduced after 6±2.5 years of anti-TNF treatment (BASRI-h-baseline: 2.4±0.7 vs. follow-up end: 2.4±0.7, P=NS and MJSW-baseline: 3.56±0.7mm vs. follow-up end: 3.59±0.79mm, P=NS). Additionally, the radiographic scores of hip remained unchanged in 21 anti-TNF treatment-naive patients with low disease activity (BASRI-h-baseline: 0.38±0.9 vs. follow-up end: 0.42±0.9, P=NS and MJSW-baseline: 4.48±0.68 mm vs. follow-up end: 4.38±0.6 mm, P=NS). Moreover patients with hip involvement were mostly men (35/38), smokers [pack-years, median/IQR: 27(5-41) vs. 8(0-20), P=0.02], with longer disease duration [median/IQR: 34(22-40) vs. 12(7-26) years, P=0.0001]. Furthermore, they had significantly higher burden of disease, as expressed by the elevated levels of CRP [median/IQR: 18.7(12-33) vs. 10.9(3.2-22), P=0.01], BASDAI-score [6.3(4.9-7.1) vs. 5(2.8-6), P=0.004], BASFI-score (5.9±2.3 vs. 3.7±2.6, P=0.0004), and the increased percentage of presence of syndesmophytes (38/38,100%). As far as potential biomarkers is concerned, anti-TNF treatment-naive patients demonstrated a 2.6-fold higher sTL1A average value (mean±SEM: 581± 157.5 pg/ml) compared with healthy controls (226.7±48.24, p=0.042). The sTL1A levels of anti-TNF-treated patients (178±42 pg/ml) were significantly lower than anti-TNF treatment-naive patients (3.3-fold decrease, P =0.0038) and comparable to those of healthy controls. A positive correlation was observed between individual levels of sTL1A and both BASDAI (Spearman r=0.3, P = 0.008) and ASDAS-CRP (Spearman r=0.22, P = 0.058) scores, suggesting that sTL1A level may reflect disease activity in patients with AS. Average serum concentrations of Periostin were higher in anti-TNF- treated (2527.4 ± 1092.4 pg/ml) compared to anti-TNF-naïve patients (1996.3 ± 975.2 pg/ml, p= 0.02) and healthy controls (629.6 ± 633.4 pg/ml, p<0.0001). A positive correlation was observed between anti-TNF-naïve patients’ serum Periostin levels and both BASDAI (Spearman r=0.5, p=0.002) and ASDAS-ESR (Spearman r=0.44, p=0.007)/ASDAS-CRP (Spearman r=0.4, p=0.014) scores. Average serum concentrations of Semaphorin-4D were higher in healthy controls (22.4± 14.2 ng/ml) compared to patients (14.07± 12.6 ng/ml, p=0.0006). Notably, Semaphorin-4D levels were higher in anti-TNF- treated (17.9± 12.5 ng/ml) compared to anti-TNF-naive patients (10.2± 11.6 ng/ml, p=0.0005) and comparable to those of healthy controls' (22.4± 14.2 ng/ml, P =0.2). After administration of anti-TNF treatment in 20 anti-TNF-naive AS patients, an elevation of average Semaphorin-4D levels was observed (10.6±12 vs. 22.2±12.7 ng/ml, p= 0.0036). Individual TL1A, Periostin, Semaphorin-4D levels were neither correlated with baseline radiographic scores of spine and hip, nor with spinal radiographic progression at the end of the 2-year follow-up period.Conclusion: In AS patients with active disease, radiographic development in the spine occurs regardless of anti-TNF treatment initiation. In contrast, radiographic hip involvement seems to stabilize during anti-TNF treatment. Thus, although TNFa inhibitors cannot arrest the osteoproductive changes in the spine, they may act beneficially to the osteodestructive ones in hip, suggesting that the disease pattern is different in axial and in peripheral skeleton. CRP is a risk factor for development of hip arthritis in AS and could be a prognostic biomarker of spinal deterioration, during anti-TNF treatment. As far as potential biomarkers are concerned, increased serum concentrations of TL1A were observed in AS patients, which associates with clinical disease activity and can be controlled by anti-TNF treatment. Periostin is upregulated in AS and positively correlated with disease activity. In contrast, Semaphorin 4D is downregulated and beneficially influenced by anti-TNF treatment in AS without correlating with disease activity. Further studies in clinical and experimental level are required for the estimation of new potential biomarker of radiographic progression in AS.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2016
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Konsta, Maria
- Κώνστα, Μαρία
Subjects
dc:subject × 14Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/39369